Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | CCR8 | P51685 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 3/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1335770 | 0.87 | CCR1 (0.58) | KMT2AKDM4EMEN1NPC1RAB9A | |
| SCHEMBL24716652 | 0.85 | KDM4E (0.54) | KMT2AKDM4EMEN1NPC1RAB9A | |
| SCHEMBL30626618 | 0.85 | KDM4E (0.54) | KMT2AKDM4EMEN1NPC1RAB9A | |
| SCHEMBL1506959 | 0.81 | HTR1A (0.53) | KMT2AKDM4EMEN1NPC1HSP90AA1 | |
| SCHEMBL3374427 | 0.81 | ERN1 (0.59) | KMT2AKDM4EMEN1NPC1RAB9A | |
| SCHEMBL13509619 | 0.78 | PSMD14 (0.51) | KMT2AKDM4EMEN1NPC1RAB9A | |
| SCHEMBL23714069 | 0.78 | KMT2A (0.65) | KMT2AKDM4EMEN1NPC1RAB9A | |
| SCHEMBL8346630 | 0.78 | NPC1 (0.55) | KMT2AKDM4EMEN1NPC1RAB9A | |
| SCHEMBL28858424 | 0.77 | CYP1A1 (0.57) | KMT2AKDM4EMEN1NPSR1 | |
| SCHEMBL12600028 | 0.76 | HTR1A (0.53) | KMT2AKDM4EMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| US-11891387-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-06 | — | — | US | disclosed |
| US-20220372030-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-24 | — | — | US | disclosed |
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1836211-A1 | MACROLIDES | Pfizer Products Incorporated (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006067589-A1 | MACROLIDES | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135447-A1 | Macrolides | CHUPAK LOUIS S | 2006-06-22 | — | — | US | disclosed |
| EP-0558950-B1 | 3-aryl-glycidic ester derivatives and process for their preparation | PHARMACIA SPA (IT) | 1996-12-04 | — | — | EP | disclosed |
| US-5436235-A | 3-aryl-glycidic ester derivatives | FARMITALIA CARLO ERBA S.R.L. (IT) | 1995-07-25 | — | — | US | disclosed |
| EP-0558950-A1 | 3-aryl-glycidic ester derivatives and process for their preparation | PHARMACIA S.p.A. (IT) | 1993-09-08 | — | — | EP | disclosed |
| US-4761475-A | 2,4-diaminopyrimidines substituted with heterobicyclomethyl radicals at the 5 position useful as antibacterials | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 1988-08-02 | — | — | US | disclosed |
| US-4587342-A | 2,4-diamino-(substituted-benzopyran(quinolyl,isoquinoly)methyl)pyrimidines useful as antibacterials | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 1986-05-06 | — | — | US | disclosed |
| EP-0051879-B1 | SUBSTITUTED PYRIMIDINES, THEIR SYNTHESIS AND COMPOSITIONS CONTAINING THEM, THEIR USE IN MEDICINE AND INTERMEDIATES FOR MAKING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-02-05 | — | — | EP | disclosed |
| EP-0051879-A2 | Substituted pyrimidines, their synthesis and compositions containing them, their use in medicine and intermediates for making them | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | KMT2A 1490/4885KDM4E 3365/4885MEN1 2100/4885 |
| US-20060135447-A1 | Macrolides | LCAT, NOP2, HDAC6 | KMT2A 2668/4885KDM4E 3426/4885MEN1 3829/4885 |
| US-11891387-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KMT2A 1490/4885KDM4E 3365/4885MEN1 2100/4885 |
| US-20220372030-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | KMT2A 1490/4885KDM4E 3365/4885MEN1 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.